195
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      ILAE Classification of the Epilepsies Position Paper of the ILAE Commission for Classification and Terminology

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          The ILAE Classification of the Epilepsies has been updated to reflect our gain in understanding of the epilepsies and their underlying mechanisms following the major scientific advances which have taken place since the last ratified classification in 1989. As a critical tool for the practising clinician, epilepsy classification must be relevant and dynamic to changes in thinking, yet robust and translatable to all areas of the globe. Its primary purpose is for diagnosis of patients, but it is also critical for epilepsy research, development of antiepileptic therapies and communication around the world. The new classification originates from a draft document submitted for public comments in 2013 which was revised to incorporate extensive feedback from the international epilepsy community over several rounds of consultation. It presents three levels, starting with seizure type where it assumes that the patient is having epileptic seizures as defined by the new 2017 ILAE Seizure Classification. After diagnosis of the seizure type , the next step is diagnosis of epilepsy type, including focal epilepsy, generalized epilepsy, combined generalized and focal epilepsy, and also an unknown epilepsy group. The third level is that of epilepsy syndrome where a specific syndromic diagnosis can be made. The new classification incorporates etiology along each stage, emphasizing the need to consider etiology at each step of diagnosis as it often carries significant treatment implications. Etiology is broken into six subgroups, selected because of their potential therapeutic consequences. New terminology is introduced such as developmental and epileptic encephalopathy. The term benign is replaced by the terms self-limited and pharmacoresponsive, to be used where appropriate. It is hoped that this new framework will assist in improving epilepsy care and research in the 21 st century.

          Related collections

          Author and article information

          Journal
          2983306R
          3565
          Epilepsia
          Epilepsia
          Epilepsia
          0013-9580
          1528-1167
          7 February 2017
          08 March 2017
          April 2017
          01 April 2018
          : 58
          : 4
          : 512-521
          Affiliations
          [1 ]Department of Medicine, The University of Melbourne, Austin Health, Melbourne, Australia
          [2 ]Department of Paediatrics, The University of Melbourne, Royal Children’s Hospital, and Florey Institute, Melbourne, Australia
          [3 ]Epilepsy Center, Child Neuropsychiatry Department, C. Poma Hospital, Mantova, Italy
          [4 ]Department of Pediatrics, University of British Columbia, British Columbia’s Children’s Hospital, Vancouver, Canada
          [5 ]Department of Neurology, New York University Langone Medical Center, New York, New York, U.S.A
          [6 ]Neurology Department of Universidade Federal de São Paulo and Hospital Universitário da Universidade de São Paulo, Brazil
          [7 ]University-Hospital-INSERM U 964-Strasbourg; IDÉE-Lyon; France
          [8 ]Indian Epilepsy Centre, New Delhi, India
          [9 ]Departments of Neurosurgery, Psychiatry and Biobehavioral Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California, U.S.A
          [10 ]Saul R. Korey Department of Neurology, Dominic k P. Purpura Department of Neuroscience and Department of Pediatrics, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, U.S.A
          [11 ]Division of Neurology, Children’s Hospital Los Angeles, U.S.A
          [12 ]C. Mondino National Neurological Institute and Clinical Pharmacology Unit, University of Pavia, Pavia, Italy
          [13 ]Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
          [14 ]Departments of Clinical Neurosciences and Community Health Sciences, University of Calgary, Alberta, Canada
          [15 ]Department of Pediatrics, Peking University First Hospital, Beijing 100034, China
          [16 ]Paediatric Neurosciences Research Group, Fraser of Allander Neurosciences Unit, Royal Hospital for Children, Glasgow, and School of Medicine, University of Glasgow, United Kingdom
          Author notes
          Corresponding author: Prof Ingrid Scheffer, Epilepsy Research Centre, 245 Burgundy St, Heidelberg, Victoria, 3084, Australia, Ph: (+613) 9035 7344, Fax: (+613) 9496 2291, scheffer@ 123456unimelb.edu.au
          Article
          PMC5386840 PMC5386840 5386840 nihpa847552
          10.1111/epi.13709
          5386840
          28276062
          f2b3a12a-a336-41d4-9c23-83c79fbf483e
          History
          Categories
          Article

          Classification,Epilepsy syndromes,Terminology,Etiology
          Classification, Epilepsy syndromes, Terminology, Etiology

          Comments

          Comment on this article

          Related Documents Log